Toronto-based Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry, has selected locations in Research Triangle Park and Durham for its global headquarters and new analytical development laboratory facilities.
"Patheon has over 300 U.S.-based customers and derives approximately 50 percent of its revenues from U.S. based companies," said Wes Wheeler, Patheon's president and CEO. "This move positions us to attract top talent from the industry and represents another step towards our vision of becoming best provider of manufacturing and development services to the pharmaceutical industry."
The analytical development facility will be built to support its current U.S.-based pharmaceutical development operations in Cincinnati and will initially offer stability studies, validation testing and analytical chemistry services. The company has already selected the RTP site and will be ready for operation in the next three months.